An Open-Label, Phase Ib Study to Assess the Long Term Safety Profile of Pazopanib in Cancer Patients.
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Pazopanib (Primary) ; Antineoplastics; Lapatinib
- Indications Glioblastoma; Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis
- 11 Apr 2018 Status changed from active, no longer recruiting to completed.
- 04 Jan 2018 Planned End Date changed from 1 Dec 2017 to 31 Mar 2018.
- 04 Jan 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Mar 2018.